Clovis LUSIVIKA NZINGA Anglais

Publications

Article dans une revue (17)

Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort study Guillaume Martin-Blondel,Paul Burgat,Valentin Leducq,Françoise Porrot,Andrea Cottignies-Calamarteet al. iScience, 2025, 28 (12), pp.114226. ⟨10.1016/j.isci.2025.114226⟩ Article dans une revue inserm-05509788v1
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis Pierre Nahon,Clovis Lusivika-Nzinga,Philippe Merle,Fabien Zoulim,Thomas Decaenset al. Journal of Hepatology, 2025, Journal of Hepatology, 83 (3), pp.701-711. ⟨10.1016/j.jhep.2025.02.008⟩ Article dans une revue hal-05088440v1
Dealing with differential misclassification of an outcome or a covariate in association studies with an internally validated sample selected not at random Júlia Lacombe Ossó,Benjamin Glemain,Céline Dorival,Hélène Blanché,Cédric Lemogneet al. BMC Medical Research Methodology, 2025, 25 (1), pp.267. ⟨10.1186/s12874-025-02698-9⟩ Article dans une revue hal-05404604v1
Dynamic personalized prediction of the individual liver‐related risk after sustained viral response in HCV patients Clémence Moreau,Marine Roux,Jérémie Riou,Clémence Canivet,Etienne Audureauet al. Journal of Viral Hepatitis, 2023, 30 (6), pp.567-577. ⟨10.1111/jvh.13830⟩ Article dans une revue hal-04194684v1
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients [letter] Timothée Bruel,Lou-Léna Vrignaud,Françoise Porrot,Isabelle Staropoli,Delphine Planaset al. Med, 2023, 4 (10), pp.664-667. ⟨10.1016/j.medj.2023.07.007⟩ Article dans une revue pasteur-04369632v1
Impact of Direct‐Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers Laurent Lam,Hélène Fontaine,Nathanael Lapidus,Céline Dorival,Jonathan Belletet al. Pharmacoepidemiology and Drug Safety, In press, ⟨10.1002/pds.5576⟩ Article dans une revue hal-03883026v1
Performance of Algorithms for Identifying Patients With Chronic Hepatitis B or C Infection in the French Health Insurance Claims Databases Using the ANRS CO22 HEPATHER Cohort Laurent Lam,Hélène Fontaine,Nathanael Lapidus,Jonathan Bellet,Clovis Lusivika‐nzingaet al. Journal of Viral Hepatitis, 2022, 30 (3), pp.232-241. ⟨10.1111/jvh.13788⟩ Article dans une revue hal-03924483v1
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort Tangui Barré,Fabrice Carrat,Clémence Ramier,Hélène Fontaine,Vincent Di Beoet al. Journal of Cannabis Research, 2022, 4 (1), pp.31. ⟨10.1186/s42238-022-00138-9⟩ Article dans une revue hal-03784790v1
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study) Guillaume Martin-Blondel,Anne-Genevieve Marcelin,Cathia Soulié,Sofia Kaisaridi,Clovis Lusivika-Nzingaet al. Journal of Infection, 2022, 84 (6), pp.e101-e104. ⟨10.1016/j.jinf.2022.04.010⟩ Article dans une revue hal-03784773v1
Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response Jessica Azzi,Céline Dorival,Carole Cagnot,Hélène Fontaine,Clovis Lusivika-Nzingaet al. Clinics and Research in Hepatology and Gastroenterology, 2022, 46 (6), pp.101923. ⟨10.1016/j.clinre.2022.101923⟩ Article dans une revue hal-03651922v1
Sotrovimab to Prevent Severe COVID-19 in High-Risk Patients Infected with Omicron BA.2 Guillaume Martin-Blondel,Anne-Geneviève Marcelin,Cathia Soulié,Sofia Kaisaridi,Clovis Lusivika-Nzingaet al. Journal of Infection, 2022, 85 (4), pp.e104-e108. ⟨10.1016/j.jinf.2022.06.033⟩ Article dans une revue hal-03777531v1
Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study Fabrice Carrat,Xavier de Lamballerie,Delphine Rahib,Hélène Blanché,Nathanael Lapiduset al. International Journal of Epidemiology, 2021, 50 (5), pp.1458-1472. ⟨10.1093/ije/dyab110⟩ Article dans une revue hal-03600604v1
Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study Laurent Lam,Hélène Fontaine,Marc Bourliere,Clovis Lusivika-Nzinga,Céline Dorivalet al. Clinics and Research in Hepatology and Gastroenterology, 2021, 45 (5), pp.101713. ⟨10.1016/j.clinre.2021.101713⟩ Article dans une revue hal-03224103v1
Sofosbuvir-Daclatasvir Is Suboptimal in Patients with Genotype 2 Chronic Hepatitis C Infection: Real-life Experience from the HEPATHER ANRS CO22 Cohort Victor Lédinghen,Clovis Lusivika-Nzinga,Jean-Pierre Bronowicki,Fabien Zoulim,Dominique Larreyet al. Journal of Viral Hepatitis, 2020, 27 (10), pp.964-973. ⟨10.1111/jvh.13321⟩ Article dans une revue hal-03704126v1
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort Anne Laurain,Sophie Metivier,Georges Haour,Dominique Larrey,Céline Dorivalet al. BMC Infectious Diseases, 2019, 19 (1), pp.300. ⟨10.1186/s12879-019-3923-5⟩ Article dans une revue hal-02120879v1
The Dynamic Effect of Direct-acting Antiviral Treatments on the Risk of Hepatocellular Carcinoma in Patients with Cirrhosis and Chronic Hepatitis C Clovis Lusivika-Nzinga,Hélène Fontaine,Céline Dorival,Mélanie Simony,Stanislas Polet al. Journal of Viral Hepatitis, 2019, 26 (12), pp.1489--1492. ⟨10.1111/jvh.13186⟩ Article dans une revue hal-03703999v1
Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination Clovis Lusivika-Nzinga,Hana Selinger-Leneman,Sophie Grabar,Dominique Costagliola,Fabrice Carrat BMC Medical Research Methodology, 2017, 17 (1), pp.160. ⟨10.1186/s12874-017-0434-1⟩ Article dans une revue inserm-02310904v1